Human antibodies as next generation therapeutics (Q34318042)

1 August 2017

1 reference

title

Human antibodies as next generation therapeutics (English)

1 reference

1 August 2017

1 reference

van Dijk MA

1

1 reference

PubMed ID

11470598

1 August 2017

van de Winkel JG

series ordinal

2

1 reference

1 August 2017

1 August 2001

1 reference

Current Opinion in Chemical Biology

1 August 2017

1 reference

1 August 2017

5

1 reference

1 August 2017

4

1 reference

1 August 2017

368-374

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

The efficient production of stable, human monoclonal antibody-secreting hybridomas from EBV-transformed lymphocytes using the mouse myeloma X63-Ag8.653 as a fusion partner.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Creating and engineering human antibodies for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Human antibodies by design.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Recombinant polyclonal antibody libraries.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Generating high-avidity human Mabs in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Production of human antibody repertoires in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Human antibodies from transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Monoclonal IgA antibodies protect against Acanthamoeba keratitis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

IgA and the IgA Fc receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Recombinant antibody constructs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Transgenic milk as a method for the production of recombinant antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Production of antibodies in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

Galactose-extended glycans of antibodies produced by transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900216-7

7 January 2021

10.1016/S1367-5931(00)00216-7

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11470598